**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76305

**Manuscript Type:** ORIGINAL ARTICLE

***Randomized Controlled Trial***

**Application of unified protocol as a transdiagnostic treatment for emotional disorders during COVID-19: An internet-delivered randomized controlled trial**

Yan K *et al*. Application of unified protocol

Kou Yan, Mohammad Hassan Yusufi, Nabi Nazari

**Kou Yan,** School of Humanities and Education, Xi'an Eurasia University, Xi'an 710065, Shaanxi Province, China

**Mohammad Hassan Yusufi,** Education Administration, Bamyan University, Bamyan 22502, Afghanistan

**Nabi Nazari,** Department of Psychology, Faculty of Human Sciences, Lorestan University, Khorramabad, Lorestan, Iran

**Author contributions:** Nazari N made significant contributions to the conceptualization and methodology of the study, and writing of the original draft; Yan K made significant contributions to the design, software, methodology, and supervision of the study; Yusufi MH made significant contributions to the preparation, data curation, writing, and revision of the draft. All authors wrote, reviewed, and edited the manuscript.

**Supported by** Shaanxi Province Education Science "13th Five-Year" Planning Topic: Drama teaching method in Application of Research of Psychological Education of Primary School students, No. SGH17H472; and Research Team Cultivation Project of Xi 'an Eurasia University: Regional Children’s Psychological Development research, No. 2021XJTD.

**Corresponding author: Nabi Nazari, PhD, Academic Fellow, Academic Research, Research Assistant, Research Assistant Professor, Senior Editor,** Department of Psychology, Faculty of Human Sciences, Lorestan University, Kamalvand St., Khorramabad 6815144316, Lorestan, Iran. nazariirani@gmail.com

**Received:** March 11, 2022

**Revised:** May 2, 2022

**Accepted:** July 25, 2022

**Published online:** August 26, 2022

**Abstract**

BACKGROUND

The coronavirus disease 2019 (COVID-19) pandemic has been an emotionally challenging time, especially for young adults. It is associated with a substantial increase in the prevalence of mental health problems, negative symptoms, and stressful experiences that compromise well-being. In low-income countries, internet-delivered psychological services could have a remarkable impact on the population’s mental health, given the lack of mental health professionals.

AIM

To investigate the efficacy of internet-delivered cognitive-behavior therapy (CBT)-transdiagnostic intervention for adults with emotional disorders.

METHODS

In this internet-delivered randomized controlled trial, 102 students with an emotional disorder (mean age = 28.20 years, standard deviation= 5.07) were randomly allocated to receive unified protocol (UP) (*n* = 51) or treatment as the usual intervention. Following a semi-structured clinical interview, participants completed an online survey including the Overall Anxiety Severity and Impairment Scale, Overall Depression Severity and Impairment Scale, Difficulties in Emotion Regulation Scale, Positive and Negative Affect Schedule, and Emotional Style Questionnaire.

RESULTS

The participants showed a high degree of adherence. In total, 78% (*n* = 40) of the experimental group participants completed the UP treatment. Considering the intention to treat procedure, the results of the analysis of covariance indicated that participants who received UP showed statistically significant changes in depression symptoms [Cohen’s *d* = -1.50 with 95% confidence interval (CI): -1.90 to -1.10], anxiety (Cohen’s *d* = -1.06 with 95%CI: -1.48 to -0.65), difficulties with emotion regulation (Cohen’s *d* = -0.33 with 95%CI: -0.7 to -0.06), positive affect (Cohen's *d* = 1.27 with 95%CI: 0.85 to 1.68), negative affect (Cohen’s *d*= -1.04 with 95%CI: -1.46 to -0.63), and healthy emotionality (Cohen’s *d* = 0.53 with 95%CI: 0.09 to 0.13) compared with the control group.

CONCLUSION

This study’s findings highlight the potential value of transdiagnostic internet-delivered programs for young adults with an emotional disorder during the COVID-19 pandemic, and expand the research examining emotional well-being improvements resulting from CBT-transdiagnostic interventions. The findings suggest that UP, which generally concentrates on reducing negative effects, can increase positive effects.

**Key Words:** Unified protocol; COVID-19; Internet-delivered; Emotion regulation; Transdiagnostic; Depression; Anxiety

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yan K, Yusufi MH, Nazari N. Application of unified protocol as a transdiagnostic treatment for emotional disorders during COVID-19: An internet-delivered randomized controlled trial. *World J Clin Cases* 2022; 10(24): 8599-8614

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i24/8599.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i24.8599

**Core Tip:** Transdiagnostic treatments may optimize mental health services during the current pandemic. The findings of this study highlight the potential value of transdiagnostic internet-delivered programs for adults. The unified protocol is a promising transdiagnostic treatment for youth with emotional disorders during the coronavirus disease 2019 pandemic. The study’s findings expand the body of research examining positive affect improvements resulting from cognitive-behavior therapy-transdiagnostic interventions.

**INTRODUCTION**

Depressive and anxiety disorders are highly prevalent conditions associated with significant impairments across all areas of life and great economic costs[1]. Before the coronavirus disease 2019 (COVID-19) outbreak, depressive and anxiety disorders were ranked as leading health burdens worldwide. Epidemiological studies have estimated a significant increase in the prevalence of major depressive disorders during the COVID-19 pandemic[2,3]. The COVID-19 outbreak has contributed to severe medical and mental health issues, particularly in vulnerable groups (*e.g.*, students and individuals with preexisting mental health problems)[4], with devastating morbidity and mortality[5,6]. Emotional disorders (*e.g.*, depression, anxiety, trauma-related, and somatic symptom disorders) are characterized by intense and unpleasant negative emotions and aversive reactions to these affective experiences, triggered by a reduced sense of emotion regulation[7]. These conditions are also comorbid and commonly coexist during the lifespan. For example, 45.7% of patients with major depressive disorder present one or more anxiety disorders[8]. The current pandemic has generated frequent and intense negative emotions[9]. Research indicates that psychiatric comorbidities or multiple co-occurring mental health problems are highly prevalent during the pandemic[10,11]. Traditional treatments or specific disorder protocols that target one diagnosis at a time (*e.g.*, major depressive disorder) may be difficult to rationalize when the clinical reality is suspected to be effective in cases with high rates of comorbidity[12]. Specific disorder treatments for primary depression are not equipped to handle comorbid conditions[13] and typically fail to produce significant outcomes in comorbid anxiety symptomatology[14]. As an alternative approach, the development of innovative transdiagnostic therapies reflects a shift from focusing on the distinctions between conditions to similarities and shared mechanisms[15].

The term transdiagnostic reflects an underlying psychological construct causally linked to the class of disorders mechanistically[16]. In the context of treatment approaches, transdiagnostic interventions focus on targeting the shared or common mechanisms implicated in the etiology or onset or maintenance of a group of disorders[17-19]. Neuroticism is a personality trait or temperamental characteristic closely linked to the emergence of anxiety and depression and the genetic risk of developing various mental and physical illnesses. Individual differences in neuroticism predict a broad range of adverse physical and psychological outcomes[20,21], such as depression[22], anxiety, and somatic symptoms[23]. Neuroticism has also been shown to be a strong predictor of internalizing symptomology during the pandemic[24].

Additionally, emotion dysregulation is a core feature of almost every major form of psychopathology diagnosis with comorbidity[25]. Individuals with emotional disorders report higher impairment in emotion regulation, including maladaptive coping strategies and reduced awareness[26]. Other contributing factors with transdiagnostic relevance mechanisms are anxiety sensitivity, intolerance uncertainty, and rumination, observed in individuals during the pandemic[27]. The dissemination and implications of integrative transdiagnostic treatments are essential to target neuroticism or emotion dysregulation, particularly during the current pandemic[28].

The unified protocol (UP), a manualized, evidence-based, cognitive-behavior therapy (CBT)-transdiagnostic, emotion-focused treatment for emotional disorders[29,30], represents an intervention explicitly developed to address temperamental vulnerabilities, in this case, neuroticism and difficulties in emotion regulation comorbid conditions. UP, with its emphasis on common neurotic processes (*e.g.*, avoidance of effective experience)[31], has the potential to facilitate training programs and address issues regarding generalizability to everyday clinical settings. Evidence represents the equivalence between UP and gold standard protocols for patients with depression and anxiety[32]. An increasing number of studies have supported the effectiveness of UP in reducing anxiety[33] and depression symptoms[34]. With COVID-19 continuing to spread around the globe, scholars anticipate a substantial increase in the rates of depression and anxiety as individuals face emotional challenges. Concerning the substantial increase in the prevalence of depression and anxiety, psychological comorbidities, and negative affective experiences (*i.e.* related to unemployment, isolation) during the current pandemic, the application of UP could be beneficial by targeting the core features of emotional disorders such as neuroticism[35] and emotion dysregulation mechanisms[36]. As such treatments tackle multiple problems and can facilitate dissemination and training using a single set of intervention protocols, they provide a more parsimonious and practical approach[37,38]. However, there is a lack of experimental data on the UP and COVID-19.

Restricting policies (*e.g.*, physical distancing) to minimize the risk of infection have made it more difficult to seek treatment. However, individuals have difficulty accessing appropriate intervention, and the COVID-19 pandemic exacerbates this. Digital mental health services (*i.e.* internet-delivered) offer the possibility of expanding the accessibility of mental health care[39]. Nevertheless, meta-analysis findings have shown that internet-based therapies are effective for anxiety and depression[40–42], with moderate to high mean effect sizes. Recent research has demonstrated that internet-based cognitive-behavioral therapies are acceptable to college students and effectively lower anxiety and depression symptoms[43]. Compared with traditional face-to-face interventions, internet-delivered interventions provide widespread access and dissemination and increase cost-effectiveness. Evidence has revealed that internet-delivered interventions are as efficacious as traditional face-to-face treatments[44,45]. Transdiagnostic, emotion-focused cognitive-behavioral treatments, such as UP for Transdiagnostic Treatment of Emotional Disorders (UP), may be particularly well suited to address the challenges practicing psychologists and their patients face during the current COVID-19 pandemic[46-48].

***Current study***

This study was conducted to examine the application of an internet-delivered CBT-transdiagnostic intervention for adults with emotional disorders. It was hypothesized that participants randomly assigned to receive UP would demonstrate significant changes in depression, anxiety, affectivity (positive and negative affects), emotion dysregulation, and healthy emotionality compared with randomly assigned participants to the treatment-as-usual group (TAU). In addition, it was hypothesized that the experimental group participants would demonstrate significant changes in the dependent variable scores compared with baseline at post-intervention.

**MATERIALS AND METHODS**

***Sample***

A total of 170 students were screened, and 102 were eligible to participate in the trial. Sixty-eight individuals were excluded from this study. Of these, thirty-eight students declined or were uninterested (without a specific reason) in participating in the study. The consort diagram is shown in Figure 1. The CONSORT 2010 checklist of information was used to report a randomized trial (Supplementary material)[49]. Individuals were eligible if they met the following criteria: aged 18 years or older with no prior experience with UP, were willing to participate and were randomly assigned to the control condition, had access to the internet and had an e-mail address, were fluent in Persian, and met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) criteria for depression or anxiety disorders[50,51]. Individuals were excluded if they met the following criteria:Presence of a severe condition that would require prioritization for treatment (*e.g.*, schizophrenia, psychosis); pregnancy or breastfeeding; clear and current or history of substance dependence disorder or alcohol, and suicide; and unstable medication regimens (*e.g.*, complex medication regimens to manage their health; unstable dose of medication over the last 3 months). The study was reviewed and approved by the internal review board of Bamyan University (Bamyan, Afghanistan). Informed consent was obtained from all subjects involved in the study.

***Measures***

The survey comprised the Overall Anxiety Severity and Impairment Scale (OASIS)[52], Overall Depression Severity and Impairment Scale (ODSIS)[53], Difficulties in Emotion Regulation Scale Short Form (DERS-SF)[54], Positive and Negative Affect Schedule (PANAS)[55], and (Emotional Style Questionnaire (ESQ[56]; Persian version[57]). The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV-TR)[58] is a semi-structured interview that evaluates diagnostic criteria. At baseline, interviews were conducted to evaluate the participants to investigate the inclusion and exclusion criteria.

***Primary outcomes***

**Anxiety:** The OASIS is a brief unidimensional transdiagnostic self-report scale developed to assess anxiety symptoms and impairment severity. Respondents rated the five items on a scale ranging from 0 (never) to 4 (extreme or all the time). Additionally, it can be used to measure anxiety disorders with comorbidities and sub-threshold anxiety symptoms. The scale had very good internal consistency (Cronbach’s α = 0.86).

**Depression:** The ODSIS is a brief unidimensional transdiagnostic self-report scale. The ODSIS is a direct adaptation of the OASIS and has been modified to assess depression. The ODSIS is a brief, five-item questionnaire that assesses dimensional depression-related symptom severity and can be used across depressive disorders with varied comorbidities. Participants rated the five items on a scale ranging from 0 (never) to 4 (extreme or all the time). The scale had very good internal consistency (Cronbach’s α = 0.87).

***Secondary outcomes***

**Affectivity:** The PANAS was employed to determine the pleasant (ten descriptors) and unpleasant (ten descriptors) feelings experienced over the past month. Participants rated the items on a five-point scale, ranging from very slightly (1) to extremely (5). The scale had very good internal consistency (α = 0.83).

**Difficulties in emotion regulation:** The DERS-SF was used to measure emotional dysregulation. The respondents rated the 18 items on a five-point scale, ranging from 1 (almost never) to 5 (almost always). Higher scores indicate greater difficulties in emotion regulation. The scale had very good internal consistency (Cronbach’s α = 0.81).

**Healthy emotionality:** The ESQ was used to measure healthy emotionality*.* Respondents rated each 24-item item on a seven-point scale ranging from 1 (strongly disagree) to 7 (strongly agree). Raw scores range from 24 to 168, with higher scores indicating higher adaptive emotional functioning. The scale had very good internal consistency (Cronbach’s α = 0.89).

***Procedure***

The current study was an internet-based, two-armed, accessor-blinded, parallel randomized controlled trial (RCT) comparing the application of an online intervention (UP) with an online TAU control group. The study (*e.g.*, all assessments and treatments) was administered *via* the internet in a university setting, including an intervention platform. The study was conducted during the COVID-19 pandemic (August 2020 to January 2021). Over 3 mo, participants were recruited through online announcements, flyers, and referrals. Additionally, the link for the study was distributed and posted on online community platforms such as university forums. Potentially eligible individuals who applied to participate in the RCT were informed of the study's objectives, advantages, hazards, session numbers, confidentiality, assurances of anonymity, and the possibility of group assignment *via* e-mail or telephone. Participants were informed that they could withdraw their consent or stop participating at any point in the study. Also, they were free to skip specific questions and continue to participate.

 Individuals who initially obtained a high score (greater than 15) on the Beck Anxiety Inventory[59] were requested to obtain informed consent. The consented participants underwent an interview to ensure that the eligibility criteria were fulfilled. Two clinical psychologists evaluated the participants' personal history, mental status, personal resources, and suicide risk through clinical interviews through 45 min of online video communication. Individuals who met theSCID-I-IVcriteriafor depression or anxiety disorders were requested to rate primary and secondary outcomes. The participants rated the primary and secondary outcomes at two time points: Time 1: pre-treatment to allocation, including baseline; and Time 2: immediately after the intervention, including posttreatment assessment. The intervention schedule is presented in Table 1.

***Sample size***

Using G\*Power software[60], a power analysis was suggested in an analysis of covariance (ANCOVA) design assuming the desired α level of 0.05, a power level of 0.8, two groups, and two measurement levels to detect a medium to large effect size[32,61]. The sample size was 82. Considering the reported dropout rate of 25%[62], the required sample size was 102.

***Randomization and blinding procedures***

The participants were randomly allocated to the intervention groups using the permuted block technique. An independent statistician generated the allocation schedule. Random sequence block sizes were generated using a computer random number generator with an equal allocation ratio. The statistician informed the observer staff and participants of the random allocation results *via* e-mail. The psychological evaluators, statisticians, and assessors who measured and recorded the data were blinded to the conditions and the participants’ groups. Participants were instructed not to share any assigned conditions or diagnostic status data.

***Interventions***

**Experimental group:** The UP is typically delivered over 12 to 14 sessions in a group format[63]. UP is a modular intervention that was administered and structured based on manuals published by Barlow *et al*[29,30,32]. UP comprises eight different treatment modules delivered in twelve 2-h weekly sessions. The UP comprises five core modules: present-focused awareness, cognitive flexibility, changing emotional behaviors, awareness and tolerance of physical sensations, and emotional exposure. A module precedes these five core modules on motivation and readiness for change and treatment engagement. Also, the second introductory module provides psychoeducation and a framework for tracking emotional experiences. After the five core modules were completed, the final module for relapse prevention was provided. Table 2 presents an overview of each module's content and intervention schedule (Supplementary material for a more thorough explanation).

**control group:** The control group received TAU as provided by the general practitioners. TAU is considered non-treatment and/or practical advice by general practitioners administered in normal care, focusing on reducing unpleasant feelings and negative emotional symptomatology. TAU was delivered in twelve 2 h weekly sessions. The participants who received the introductory modules of UP included four psychoeducation sessions. Specifically, the TAU comprises three parts: four sessions of psychoeducation, four sessions of COVID-19 consideration, and four sessions of sharing experiences.

***Risk***

For participants with higher concerns related to psychological states, support was delivered by clinical psychologists and general practitioners *via* e-mail and telephone. Clinical team members received a comprehensive refreshment course in the context of psychological assessments*,* structured interviews, and ethics in clinical research.

***Statistical analysis***

Data were analyzed using SPSS with a two-sided 5% significance level. Based on the intent-to-treat procedure, the data for all randomized participants were considered in the final analysis. The last observation-carried-forward method was considered the next point for dropping data to handle missing data. Descriptive statistics were utilized to present the means and standard deviation for continuous variables and numbers or percentages for categorical variables. The parametric test of ANCOVA was performed to investigate UP efficacy compared with TAU, with the time1 (baseline) collected data as covariate scores to control preexisting group differences. The paired *t*-test was conducted to investigate within-group changes. Effect sizes are reported as partial eta-squared. Also, the standardized effect size (Cohen's *d*)was calculated for pretreatment and posttreatment changes based on the means and standard deviations. Effect size values were interpreted conservatively, with 0.2, 0.5, and 0.8 reflecting small, medium, and large treatment effects[64].

**RESULTS**

***Descriptive characteristics***

The baseline characteristics of the study participants are presented in Table 3. At baseline, independent *t*-tests showed no significant group differences in age, primary outcomes, or secondary outcomes (*P* > 0.05), indicating successful randomization. The sample comprised 102 adults aged 20 years to 39 years. The mean age was 28.07 years [standard deviation (SD)= 5.07]. At the end of the study, 78% (*n* = 40) of the experimental group participants completed UP treatment sessions and completed the assessment protocol. Additionally, 37% (*n* = 20) of participants left the control group. In total, 70% (*n* = 71) of the participants completed the course.

***Treatment results***

Table 4 shows the results of the parametric test of ANCOVA to compare the effectiveness of the unified protocol intervention with TAU at posttreatment (Time 2). At the end of the study, the ANCOVA results revealed that students who received the UP intervention had a statistically significant reduction in ODSIS score compared with those who received TAU, Cohen’s *d* = -1.50 with 95%CI: -1.90 to -1.06; mean different = 4.08, standard error (SE) = 0.52, *P* < 0.001, with 95%CI: 3.05 to 5.11. ANCOVA results also revealed that students who received UP intervention demonstrated a statistically significant reduction in OASIS score compared with those who received TAU, Cohen’s *d* = -1.06 with 95%CI: -1.48 to -0.65; meandifferent = 2.47, SE = 0.56, *P* < 0.001, with 95%CI: 1.39 to 3.56.

At the end of the study, the results of ANCOVA revealed that students who received UP intervention demonstrated a statistically significant reduction in DERS score compared with those who received TAU, Cohen’s *d* = -0.33 with 95%CI: -0.7 to -0.06; mean different = 4.19, SE = 1.63, *P* = 0.01, with 95%CI: 0.95 to 7.43. ANCOVA results also revealed that students who received the UP intervention demonstrated a statistically significant increase in ESQ score compared with those who received TAU, Cohen’s *d* = 0.53, 95%CI: 0.14 to 0.93; mean different = -0.8.76, SE = 2.44, *P* =0.001, with 95%CI: -13.56 to -3.92.

At the end of the study, the results of ANCOVA also revealed that students who received UP intervention demonstrated a statistically significant increase in PANAS-PA score compared with those who received TAU; Cohen’s *d* = 1.27 with 95%CI: 0.85 to 1.68; mean different = -4.41, SE = 0.69, *P* < 0.001, with 95%CI: -5.79 to -3.04. ANCOVA results also revealed that students who received UP intervention demonstrated a statistically significant reduction in PANAS-NA score compared with those who received TAU, Cohen’s *d* = -1.04 with 95%CI: -1.46 to -0.63; mean different = 3.72, SE = 0.81, *P* < 0.001, with 95%CI: 2.14 to 5.37. Means and SDs are presented at Time 1 and 2 (table 5).

The paired *t*-test was conducted to calculate the within-group effect size post-intervention compared with baseline. These findings revealed that the experimental group participants significantly demonstrated improvement in the dependent variable scores post-intervention (Table 6). The results showed no significant differences for the control group participants between Time 2 and Time 1.

**DISCUSSION**

The outbreak of COVID-19 is an emotionally challenging time, especially for young adults, and is associated with a range of mental health problems, negative emotions, and stressful experiences that compromise a well-being. However, little evidence is available. The study was conducted to examine the application of an internet-delivered CBT-trans-diagnostic intervention for adults with emotional disorders. The study’s findings show that an internet-delivered trans-diagnostic CBT protocol is an effective intervention for individuals with depression and anxiety during COVID-19. At posttreatment, the students who received the UP intervention showed significant changes in depression, anxiety, emotion dysregulation, affectivity, and healthy emotionality outcomes compared with those who participated in the TAU intervention. Our findings revealed significant changes in depression, anxiety, worry, emotion regulation, and affectivity measures in the unified protocol group posttreatment relative to baseline. There were no significant changes in the dependent variables in the control group at posttreatment relative to baseline. The stressful pandemic situations may have been a confounding factor that may have elevated mental health problems and higher than usual daily psychological life distress among the control group participants.

As an emotion-focused intervention, the core modules of UP are relevant to depression and anxiety. The improvement of emotion regulation can be associated with improved depression and anxiety symptoms[65,66]. A large body of evidence has examined the relationships and influences of emotional regulation in the treatment of depression[34,67,68], anxiety disorders[69,70], psychological distress[71], and rumination[72]. Depressed individuals lack emotional regulation skills, which results in higher rumination, avoidance, and suppression of positive emotion[73]. Individuals with higher depression report more ineffective coping strategies (*e.g.*, rumination, self-blame) and a lower prevalence of adaptive emotion regulation behaviors (*e.g.*, positive reappraisal, acceptance)[74] when experiencing negative emotions[75]. Moreover, psychological distress is associated with maladaptive or ineffective reappraisal functions and mood fluctuations, which contribute to depression, anxiety, and mental health problems[76].

The study revealed surprising findings. Large effect sizes were found in the negative and positive effects, with a greater effect on positive affect than negative affect. The decrease in negative affect scores confirms the UP protocol's theory that a mechanistically transdiagnostic treatment explicitly targets and reduces negative effects[19] as a psychopathology mechanism associated with the etiology of emotional disorders[77]. Despite the benefits of targeting positive emotions for physical and emotional well-being, most psychological interventions focus on targeting negative affect. Consequently, trans-diagnostic interventions for emotional disorders (*e.g.*, UP) remain focused on evaluating outcomes of reduced negative affectivity symptoms. While UP initially focuses on reducing negative affect. A few investigations have revealed that the UP application may also promote positive affect[33,78,79]. Anxiety and depression have also been associated with lower levels of positive affect (*i.e.* extraversion) and a lower tendency to experience the world in an energetic and sociable way[80]. The study's findings expand the body of research that examines positive affect improvements resulting from CBT-transdiagnostic interventions. The findings are promising, as they suggest that UP can promote positive affect and healthy emotionality, the constructs linked with emotional well-being and flourishing[81,82].

The current study could develop the UP, consisting of five core modules supported by the introductory modules, to teach clients how to accept and experience emotional distress while responding to them in more adaptive ways. As the treatment progresses, thoughts, physical feelings, and behaviors are examined in-depth, emphasizing the dysfunctional emotion regulation strategies that the patient has developed over time. Psychoeducational modules have increased patients' readiness and motivation for change and facilitated coping by developing knowledge about the components (*i.e.* behavioral, cognitive, and psychological) of emotions and their interaction. The UP core modules concentrate on skills and strategies to target deficits in emotion regulation and facilitate more adaptive responses[30]. Individuals with depression experience deficits in mindful awareness of their emotions and experiences, particularly for nonjudgmental awareness and allowing oneself to notice emotions without triggering a repetitive negative thinking process such as rumination[83,84]. There is also evidence that mindfulness is an effective strategy to facilitate inhibitory learning in exposure therapy. Mindfulness training is associated with decreased reliance on strategies such as rumination and over engagement and a greater ability to tolerate negative emotions[85]. Individuals affected by adverse events may misinterpret abnormal bodily sensations as severe condition warning signs[86]. Accurate knowledge concerning COVID-19 infection may inhibit an automatic fear response and suppress an initial emotional and bodily fear reaction[87,88]. The higher levels of self-awareness lead to a clear recognition of the triggering of negative effects and facilitate adaptive emotional functioning through mindful attention toward unpleasant bodily sensations[89]. As another UP component, interoceptive exposure (IE) was originally designed to target fearful reactions and anxious sensitivity toward bodily sensations linked with anxiety and fear generated by stressful experiences[90]. IE effectively reduces the fear of bodily sensations, treats anxiety sensitivity, and promotes self-regulated social interaction abilities[68].

The feasibility of the internet-delivered UP in a group setting was evaluated. While emotion dysregulation is linked to a lower desire to engage in the treatment, the sample is characterized as challenging to treat[91]. Overall, participants had a high degree of adherence, and the treatment was well tolerated. Previous studies have substantially improved patient engagement and clinical outcomes in the guided internet-delivered group interventions[92-94].

***Limitations***

The trial's findings must be viewed in light of several limitations. The participants were students who were so well educated, which may have aided individuals' capacity to develop more UP and reduce generalizability. The next limitation was the anticipated dropout rate (25%), which was lower than the actual dropout rate (30%). With an interdisciplinary approach to attrition incorporating a range of technological, environmental, and individual factors, future studies may be required to explain participants' adherence comprehensively and improve retention in internet-delivered interventions. The next limitation was that the lack of follow-up made it difficult to assess prevention effects. Additionally, the study had no follow-up. Therefore, it was not easy to assess the long-term effects. Further studies with larger sample sizes and longer follow-up periods are required to replicate the findings of this study. The SCID-I-IV application at enrollment and the end of the study was a strength of this research.

**CONCLUSION**

Despite the limitations, the findings developed the unified protocol as a promising transdiagnostic treatment for youth with emotional disorders during the COVID-19 pandemic. UP has the potential to simplify training efforts while also addressing concerns about generalizability to routine care settings. Addressing these current barriers to widespread dissemination and implementation of evidence-based practice treatments has implications for bridging the science-to-service gap. The present study's findings provide further evidence of internet-delivered CBT transdiagnostic interventions for improvements in depressive and anxiety disorders. In the challenging emotional events generated by the COVID-19 pandemic, the UP may be particularly well-suited to help individuals manage their experienced emotional problems. Additionally, from a global mental health perspective, a unified transdiagnostic treatment can potentially serve as a promising intervention approach that would be more cost-effective and may help to increase the availability of evidence-based treatments for emotional disorders, affordability of dissemination of a single protocol *vs* multiple protocols, and a decreased need for clinical observations by trained health professionals[95].

Further studies are required to assess the cost-effectiveness and economic evaluations of internet-delivered UP with larger samples, as this has not yet been formally evaluated. There would be value in adding qualitative components into future trials to establish the acceptance of unified protocol interventions for clinicians and clients. With an interdisciplinary approach to attrition incorporating a range of technological, environmental, and individual factors, future studies may be required to comprehensively explain participants’ adherence and improve retention in internet-delivered interventions.

**ARTICLE HIGHLIGHTS**

***Research background***

Depressive and anxiety disorders represent one of the greatest burdens among human diseases worldwide. These emotionally difficult conditions often manifest as comorbidities. A growing body of evidence indicates that the trans-diagnostic approach for treating these disorders is safe, feasible, and efficient.

***Research motivation***

Restricted policies (*e.g.*, physical distancing) to minimize the risk of infection have made it more difficult to seek and attend treatment. The majority of individuals with mental health problems remain untreated. Internet-based interventions can help to address existing barriers. Also, trans-diagnostic, emotion-focused cognitive-behavioral treatments, such as unified protocol (UP), may be particularly well suited to address the challenges practicing psychologists and their patients face during the current coronavirus disease 2019 (COVID-19) pandemic.

***Research objectives***

This study was conducted to examine the application of an internet-delivered cognitive-behavior therapy (CBT)-transdiagnostic intervention for adults with emotional disorders.

***Research methods***

In this internet-delivered two-armed, accessor-blinded, parallel randomized controlled trial, 102 students with an emotional disorder were randomly allocated to receive UP or treatment as the usual interventions. Following a semi-structured clinical interview, participants completed an online survey, including the Overall Anxiety Severity and Impairment Scale, Overall Depression Severity and Impairment Scale, Difficulties in Emotion Regulation Scale, Positive and Negative Affect Schedule, and Emotional Style Questionnaire.

***Research results***

The findings of the current trial highlight the considerable potential of internet-delivered CBT programs, such as the UP, in improving access to online psychotherapy for affected adults by the pandemic. Our findings revealed significant changes in depression, anxiety, worry, emotion regulation, and affectivity measures in the unified protocol group posttreatment relative to baseline. There were no significant changes in the dependent variables in the control group at posttreatment relative to baseline.

***Research conclusions***

Transdiagnostic treatments target shared mechanisms between disorders to facilitate change across diagnoses. Overall, the findings support that the unified protocol could be an additional efficient as a parsimonious, transdiagnostic treatment of emotional disorders for young adults with emotional disorders during the current pandemic.

***Research perspectives***

From a global mental health perspective, a unified transdiagnostic treatment can potentially serve as a promising intervention approach that would be more cost-effective and may help to increase the availability of evidence-based treatments for emotional disorders, affordability of dissemination of a single protocol *vs* multiple protocols, and a decreased need for clinical observations by trained health professionals. With an interdisciplinary approach to attrition incorporating a range of technological, environmental, and individual factors, future studies may be required to comprehensively explain participants’ adherence and improve retention in internet-delivered interventions.

**REFERENCES**

1 **GBD 2019 Diseases and Injuries Collaborators**. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**: 1204-1222 [PMID: 33069326 DOI: 10.1016/S0140-6736(20)30925-9]

2 **COVID-19 Mental Disorders Collaborators**. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021; **398**: 1700-1712 [PMID: 34634250 DOI: 10.1016/S0140-6736(21)02143-7]

3 **Ettman CK**, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. *JAMA Netw Open* 2020; **3**: e2019686 [PMID: 32876685 DOI: 10.1001/jamanetworkopen.2020.19686]

4 **Bai W**, Cai H, Liu S, Chen X, Sha S, Cheung T, Lin JJ, Cui X, Ng CH, Xiang YT. Anxiety and depressive symptoms in college students during the late stage of the COVID-19 outbreak: a network approach. *Transl Psychiatry* 2021; **11**: 638 [PMID: 34921138 DOI: 10.1038/s41398-021-01738-4]

5 **Shi L**, Lu ZA, Que JY, Huang XL, Liu L, Ran MS, Gong YM, Yuan K, Yan W, Sun YK, Shi J, Bao YP, Lu L. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic. *JAMA Netw Open* 2020; **3**: e2014053 [PMID: 32609353 DOI: 10.1001/jamanetworkopen.2020.14053]

6 **Nochaiwong S**, Ruengorn C, Thavorn K, Hutton B, Awiphan R, Phosuya C, Ruanta Y, Wongpakaran N, Wongpakaran T. Global prevalence of mental health issues among the general population during the coronavirus disease-2019 pandemic: a systematic review and meta-analysis. *Sci Rep* 2021; **11**: 10173 [PMID: 33986414 DOI: 10.1038/s41598-021-89700-8]

7 **Bullis JR**, Boettcher H, Sauer-Zavala S, Farchione TJ, Barlow DH. What is an emotional disorder? A transdiagnostic mechanistic definition with implications for assessment, treatment, and prevention. *Clin Psychol Sci Pract* 2019; **26**: 1-19 [DOI: 10.1111/cpsp.12278]

8 **Kessler RC**, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, Bunting B, Demyttenaere K, Florescu S, de Girolamo G, Gureje O, He Y, Hu C, Huang Y, Karam E, Kovess-Masfety V, Lee S, Levinson D, Medina Mora ME, Moskalewicz J, Nakamura Y, Navarro-Mateu F, Browne MA, Piazza M, Posada-Villa J, Slade T, Ten Have M, Torres Y, Vilagut G, Xavier M, Zarkov Z, Shahly V, Wilcox MA. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. *Epidemiol Psychiatr Sci* 2015; **24**: 210-226 [PMID: 25720357 DOI: 10.1017/S2045796015000189]

9 **Nazari N**, Safitri S, Usak M, Arabmarkadeh A, Griffiths MD. Psychometric Validation of the Indonesian Version of the Fear of COVID-19 Scale: Personality Traits Predict the Fear of COVID-19. *Int J Ment Health Addict* 2021: 1-17 [PMID: 34456653 DOI: 10.1007/s11469-021-00593-0]

10 **Groen RN**, Ryan O, Wigman JTW, Riese H, Penninx BWJH, Giltay EJ, Wichers M, Hartman CA. Comorbidity between depression and anxiety: assessing the role of bridge mental states in dynamic psychological networks. *BMC Med* 2020; **18**: 308 [PMID: 32988400 DOI: 10.1186/s12916-020-01738-z]

11 **Nazari N**, Sadeghi M, Samusenkov V, Aligholipour A. Factors associated with insomnia among frontline nurses during COVID-19: a cross-sectional survey study. *BMC Psychiatry* 2022; **22**: 40 [PMID: 35038999 DOI: 10.1186/s12888-022-03690-z]

12 **Holmes EA**, Ghaderi A, Harmer CJ, Ramchandani PG, Cuijpers P, Morrison AP, Roiser JP, Bockting CLH, O'Connor RC, Shafran R, Moulds ML, Craske MG. The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science. *Lancet Psychiatry* 2018; **5**: 237-286 [PMID: 29482764 DOI: 10.1016/S2215-0366(17)30513-8]

13 **Newby JM**, McKinnon A, Kuyken W, Gilbody S, Dalgleish T. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. *Clin Psychol Rev* 2015; **40**: 91-110 [PMID: 26094079 DOI: 10.1016/j.cpr.2015.06.002]

14 **Weitz E**, Kleiboer A, van Straten A, Cuijpers P. The effects of psychotherapy for depression on anxiety symptoms: a meta-analysis. *Psychol Med* 2018; **48**: 2140-2152 [PMID: 29361995 DOI: 10.1017/S0033291717003622]

15 **Clark LA**, Cuthbert B, Lewis-Fernández R, Narrow WE, Reed GM. Three Approaches to Understanding and Classifying Mental Disorder: ICD-11, DSM-5, and the National Institute of Mental Health's Research Domain Criteria (RDoC). *Psychol Sci Public Interest* 2017; **18**: 72-145 [PMID: 29211974 DOI: 10.1177/1529100617727266]

16 **Sauer-Zavala S**, Gutner CA, Farchione TJ, Boettcher HT, Bullis JR, Barlow DH. Current Definitions of "Transdiagnostic" in Treatment Development: A Search for Consensus. *Behav Ther* 2017; **48**: 128-138 [PMID: 28077216 DOI: 10.1016/j.beth.2016.09.004]

17 **Mansell W**. Transdiagnostic psychiatry goes above and beyond classification. *World Psychiatry* 2019; **18**: 360-361 [PMID: 31496093 DOI: 10.1002/wps.20680]

18 **Ellard KK**, Fairholme CP, Boisseau CL, Farchione TJ, Barlow DH. Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders: Protocol Development and Initial Outcome Data. *Cogn Behav Pract* 2010; **17**: 88-101 [PMID: 33762811 DOI: 10.1016/j.cbpra.2009.06.002]

19 **Brown TA**, Barlow DH. A proposal for a dimensional classification system based on the shared features of the DSM-IV anxiety and mood disorders: implications for assessment and treatment. *Psychol Assess* 2009; **21**: 256-271 [PMID: 19719339 DOI: 10.1037/a0016608]

20 **Boswell JF**, Anderson LM, Barlow DH. An idiographic analysis of change processes in the unified transdiagnostic treatment of depression. *J Consult Clin Psychol* 2014; **82**: 1060-1071 [PMID: 25045911 DOI: 10.1037/a0037403]

21 **Sauer-Zavala S**, Fournier JC, Jarvi Steele S, Woods BK, Wang M, Farchione TJ, Barlow DH. Does the unified protocol really change neuroticism? Results from a randomized trial. *Psychol Med* 2021; **51**: 2378-2387 [PMID: 32312357 DOI: 10.1017/S0033291720000975]

22 **Yao N**, Nazari N, Veiskarami HA, Griffiths MD. The role of healthy emotionality in the relationship between fear of COVID-19 and mental health problems: a cross-sectional study. *Cogn Process* 2022 [PMID: 35790620 DOI: 10.1007/s10339-022-01101-5]

23 **Strickhouser JE**, Zell E, Krizan Z. Does personality predict health and well-being? A metasynthesis. *Health Psychol* 2017; **36**: 797-810 [PMID: 28277701 DOI: 10.1037/hea0000475]

24 **Nikčević AV**, Spada MM. The COVID-19 anxiety syndrome scale: Development and psychometric properties. *Psychiatry Res* 2020; **292**: 113322 [PMID: 32736267 DOI: 10.1016/j.psychres.2020.113322]

25 **Nazari N**, Aligholipour A, Sadeghi M. Transdiagnostic treatment of emotional disorders for women with multiple sclerosis: a randomized controlled trial. *BMC Womens Health* 2020; **20**: 245 [PMID: 33129298 DOI: 10.1186/s12905-020-01109-z]

26 **Kirwan M,** Svenson DW, Pickett SM, Parkhill MR. Emotion regulation as a mediator between sleep quality and interpersonal aggression. *Pers Individ Dif* 2019; **148**: 32-37 [DOI: 10.1016/j.paid.2019.05.018]

27 **Wu X**, Nazari N, Griffiths MD. Using Fear and Anxiety Related to COVID-19 to Predict Cyberchondria: Cross-sectional Survey Study. *J Med Internet Res* 2021; **23**: e26285 [PMID: 34014833 DOI: 10.2196/26285]

28 **Ehrenreich-May J**, Halliday ER, Karlovich AR, Gruen RL, Pino AC, Tonarely NA. Brief Transdiagnostic Intervention for Parents With Emotional Disorder Symptoms During the COVID-19 Pandemic: A Case Example. *Cogn Behav Pract* 2021; **28**: 690-700 [PMID: 34629841 DOI: 10.1016/j.cbpra.2021.01.002]

29 **Barlow DH**, Farchione TG, Sauer-Zavala S, Latin HM, Ellard KK, Bullis JR, Bentley KH, Boettcher HT, Cassiello-Robbins C. Unified Protocol for Transdiagnostic Treatment of Emotional Disorders: Workbook. 2nd Ed. New York, NY: Oxford University Press; 2017

30 **Barlow DH**, Farchione T. Applications of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. 2nd Ed. New York, NY: Oxford University Press; 2017

31 **Sauer-Zavala S**, Wilner JG, Barlow DH. Addressing neuroticism in psychological treatment. *Personal Disord* 2017; **8**: 191-198 [PMID: 29120218 DOI: 10.1037/per0000224]

32 **Barlow DH**, Farchione TJ, Bullis JR, Gallagher MW, Murray-Latin H, Sauer-Zavala S, Bentley KH, Thompson-Hollands J, Conklin LR, Boswell JF, Ametaj A, Carl JR, Boettcher HT, Cassiello-Robbins C. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Compared With Diagnosis-Specific Protocols for Anxiety Disorders: A Randomized Clinical Trial. *JAMA Psychiatry* 2017; **74**: 875-884 [PMID: 28768327 DOI: 10.1001/jamapsychiatry.2017.2164]

33 **Sakiris N**, Berle D. A systematic review and meta-analysis of the Unified Protocol as a transdiagnostic emotion regulation based intervention. *Clin Psychol Rev* 2019; **72**: 101751 [PMID: 31271848 DOI: 10.1016/j.cpr.2019.101751]

34 **Sauer-Zavala S**, Bentley KH, Steele SJ, Tirpak JW, Ametaj AA, Nauphal M, Cardona N, Wang M, Farchione TJ, Barlow DH. Treating depressive disorders with the Unified Protocol: A preliminary randomized evaluation. *J Affect Disord* 2020; **264**: 438-445 [PMID: 31759672 DOI: 10.1016/j.jad.2019.11.072]

35 **Sherman JA**, Tonarely NA, Ehrenreich-May J. Targeting Comorbid Anxiety and Depression Using the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents. *Clin Case Stud* 2018; **17**: 59-76 [DOI: 10.1177/1534650117753671]

36 **Kennedy SM**, Bilek EL, Ehrenreich-May J. A Randomized Controlled Pilot Trial of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children. *Behav Modif* 2019; **43**: 330-360 [PMID: 29374963 DOI: 10.1177/0145445517753940]

37 **Norton PJ**. A randomized clinical trial of transdiagnostic cognitve-behavioral treatments for anxiety disorder by comparison to relaxation training. *Behav Ther* 2012; **43**: 506-517 [PMID: 22697440 DOI: 10.1016/j.beth.2010.08.011]

38 **Norton PJ**, Roberge P. Transdiagnostic Therapy. *Psychiatr Clin North Am* 2017; **40**: 675-687 [PMID: 29080593 DOI: 10.1016/j.psc.2017.08.003]

39 **Lattie EG**, Stiles-Shields C, Graham AK. An overview of and recommendations for more accessible digital mental health services. *Nat Rev Psychol* 2022: **1**: 87–100 [DOI: 10.1038/s44159-021-00003-1]

40 **Bücker L**, Gehlenborg J, Moritz S, Westermann S. A randomized controlled trial on a self-guided Internet-based intervention for gambling problems. *Sci Rep* 2021; **11**: 13033 [PMID: 34158553 DOI: 10.1038/s41598-021-92242-8]

41 **Kladnitski N**, Smith J, Uppal S, James MA, Allen AR, Andrews G, Newby JM. Transdiagnostic internet-delivered CBT and mindfulness-based treatment for depression and anxiety: A randomised controlled trial. *Internet Interv* 2020; **20**: 100310 [PMID: 32140427 DOI: 10.1016/j.invent.2020.100310]

42 **Mira A**, Bretón-López J, García-Palacios A, Quero S, Baños RM, Botella C. An Internet-based program for depressive symptoms using human and automated support: a randomized controlled trial. *Neuropsychiatr Dis Treat* 2017; **13**: 987-1006 [PMID: 28408833 DOI: 10.2147/NDT.S130994]

43 **Karyotaki E**, Klein AM, Ciharova M, Bolinski F, Krijnen L, de Koning L, de Wit L, van der Heijde CM, Ebert DD, Riper H, Batelaan N, Vonk P, Auerbach RP, Kessler RC, Bruffaerts R, Struijs S, Wiers RW, Cuijpers P. Guided internet-based transdiagnostic individually tailored Cognitive Behavioral Therapy for symptoms of depression and/or anxiety in college students: A randomized controlled trial. *Behav Res Ther* 2022; **150**: 104028 [PMID: 35066365 DOI: 10.1016/j.brat.2021.104028]

44 **Andersson G**, Titov N, Dear BF, Rozental A, Carlbring P. Internet-delivered psychological treatments: from innovation to implementation. *World Psychiatry* 2019; **18**: 20-28 [PMID: 30600624 DOI: 10.1002/wps.20610]

45 **Luo C**, Sanger N, Singhal N, Pattrick K, Shams I, Shahid H, Hoang P, Schmidt J, Lee J, Haber S, Puckering M, Buchanan N, Lee P, Ng K, Sun S, Kheyson S, Chung DC, Sanger S, Thabane L, Samaan Z. A comparison of electronically-delivered and face to face cognitive behavioural therapies in depressive disorders: A systematic review and meta-analysis. *EClinicalMedicine* 2020; **24**: 100442 [PMID: 32775969 DOI: 10.1016/j.eclinm.2020.100442]

46 **Cassiello-Robbins C**, Rosenthal MZ, Ammirati RJ. Delivering Transdiagnostic Treatment Over Telehealth During the COVID-19 Pandemic: Application of the Unified Protocol. *Cogn Behav Pract* 2021; **28**: 555-572 [PMID: 34108830 DOI: 10.1016/j.cbpra.2021.04.007]

47 **Osma J**, Peris-Baquero O, Suso-Ribera C, Farchione TJ, Barlow DH. Effectiveness of the Unified Protocol for transdiagnostic treatment of emotional disorders in group format in Spain: Results from a randomized controlled trial with 6-months follow-up. *Psychother Res* 2022; **32**: 329-342 [PMID: 34132170 DOI: 10.1080/10503307.2021.1939190]

48 **Caiado B**, Góis A, Pereira B, Canavarro MC, Moreira H. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children (UP-C) in Portugal: Feasibility Study Results. *Int J Environ Res Public Health* 2022; **19** [PMID: 35162806 DOI: 10.3390/ijerph19031782]

49 **Schulz KF**, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. *J Pharmacol Pharmacother* 2010; **1**: 100-107 [PMID: 21350618 DOI: 10.4103/0976-500X.72352]

50 **First MB**, Williams JB, Spitzer RL. Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). New York: Biometrics Research, New York State Psychiatric Institute, 2002

51 **First MB**, Williams JB, Spitzer RL. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute, 2002

52 **Norman SB**, Allard CB, Trim RS, Thorp SR, Behrooznia M, Masino TT, Stein MB. Psychometrics of the Overall Anxiety Severity and Impairment Scale (OASIS) in a sample of women with and without trauma histories. *Arch Womens Ment Health* 2013; **16**: 123-129 [PMID: 23296334 DOI: 10.1007/s00737-012-0325-8]

53 **Bentley KH**, Gallagher MW, Carl JR, Barlow DH. Development and validation of the Overall Depression Severity and Impairment Scale. *Psychol Assess* 2014; **26**: 815-830 [PMID: 24708078 DOI: 10.1037/a0036216]

54 **Kaufman EA**, Xia M, Fosco G, Yaptangco M, Skidmore CR, Crowell SE. The Difficulties in Emotion Regulation Scale Short Form (DERS-SF): Validation and Replication in Adolescent and Adult Samples. *J Psychopathol Behav Assess* 2016; **38**: 443-455 [DOI: 10.1007/s10862-015-9529-3]

55 **Watson D**, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988; **54**: 1063-1070 [PMID: 3397865 DOI: 10.1037//0022-3514.54.6.1063]

56 **Kesebir P**, Gasiorowska A, Goldman R, Hirshberg MJ, Davidson RJ. Emotional Style Questionnaire: A multidimensional measure of healthy emotionality. *Psychol Assess* 2019; **31**: 1234-1246 [PMID: 31259572 DOI: 10.1037/pas0000745]

57 **Nazari N**, Griffiths MD. Psychometric validation of the Persian version of the Emotional Style Questionnaire. *Curr Psychol* 2020: 1-13 [PMID: 33262561 DOI: 10.1007/s12144-020-01205-1]

58 **Sharifi V**, Assadi SM, Mohammadi MR, Amini H, Kaviani H, Semnani Y, Shabani A, Shahrivar Z, Davari-Ashtiani R, Shooshtari MH, Seddigh A, Jalali M. A Persian translation of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: psychometric properties. *Compr Psychiatry* 2009; **50**: 86-91 [PMID: 19059520 DOI: 10.1016/j.comppsych.2008.04.004]

59 **Beck AT**, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol* 1988; **56**: 893-897 [PMID: 3204199 DOI: 10.1037//0022-006x.56.6.893]

60 **Faul F**, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G\*Power 3.1: tests for correlation and regression analyses. *Behav Res Methods* 2009; **41**: 1149-1160 [PMID: 19897823 DOI: 10.3758/BRM.41.4.1149]

61 **Carlucci L**, Saggino A, Balsamo M. On the efficacy of the unified protocol for transdiagnostic treatment of emotional disorders: A systematic review and meta-analysis. *Clin Psychol Rev* 2021; **87**: 101999 [PMID: 34098412 DOI: 10.1016/j.cpr.2021.101999]

62 **Andrews G**, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PLoS One* 2010; **5**: e13196 [PMID: 20967242 DOI: 10.1371/journal.pone.0013196]

63 **Osma J**, Suso-Ribera C, García-Palacios A, Crespo-Delgado E, Robert-Flor C, Sánchez-Guerrero A, Ferreres-Galan V, Pérez-Ayerra L, Malea-Fernández A, Torres-Alfosea MÁ. Efficacy of the unified protocol for the treatment of emotional disorders in the Spanish public mental health system using a group format: study protocol for a multicenter, randomized, non-inferiority controlled trial. *Health Qual Life Outcomes* 2018; **16**: 46 [PMID: 29530035 DOI: 10.1186/s12955-018-0866-2]

64 **Cohen J**. A power primer. *Psychol Bull* 1992; **112**: 155-159 [PMID: 19565683 DOI: 10.1037//0033-2909.112.1.155]

65 **Sloan E**, Hall K, Moulding R, Bryce S, Mildred H, Staiger PK. Emotion regulation as a transdiagnostic treatment construct across anxiety, depression, substance, eating and borderline personality disorders: A systematic review. *Clin Psychol Rev* 2017; **57**: 141-163 [PMID: 28941927 DOI: 10.1016/j.cpr.2017.09.002]

66 **Kring AM**, Sloan DM. Emotion Regulation and Psychopathology: A Transdiagnostic Approach to Etiology and Treatment. New York: Guilford Press, 2010: 468

67 **Karyotaki E**, Klein AM, Riper H, Wit L, Krijnen L, Bol E, Bolinski F, Burger S, Ebert DD, Auerbach RP, Kessler RC, Bruffaerts R, Batelaan N, van der Heijde CM, Vonk P, Kleiboer A, Wiers RW, Cuijpers P. Examining the effectiveness of a web-based intervention for symptoms of depression and anxiety in college students: study protocol of a randomised controlled trial. *BMJ Open* 2019; **9**: e028739 [PMID: 31092668 DOI: 10.1136/bmjopen-2018-028739]

68 **González-Robles A**, Díaz-García A, García-Palacios A, Roca P, Ramos-Quiroga JA, Botella C. Effectiveness of a Transdiagnostic Guided Internet-Delivered Protocol for Emotional Disorders Versus Treatment as Usual in Specialized Care: Randomized Controlled Trial. *J Med Internet Res* 2020; **22**: e18220 [PMID: 32673226 DOI: 10.2196/18220]

69 **Klemanski DH**, Curtiss J, McLaughlin KA, Nolen-Hoeksema S. Emotion Regulation and the Transdiagnostic Role of Repetitive Negative Thinking in Adolescents with Social Anxiety and Depression. *Cognit Ther Res* 2017; **41**: 206-219 [PMID: 28579659 DOI: 10.1007/s10608-016-9817-6]

70 **Lopez ME**, Thorp SR, Dekker M, Noorollah A, Stoddard JA. The unified protocol for anxiety and depression with comorbid borderline personality disorder: a single case design clinical series. *Cogn Behav Ther* 2019; **12**: e37 [DOI: 10.1017/S1754470X19000254]

71 **MacNamara A**, Kotov R, Hajcak G. Diagnostic and symptom-based predictors of emotional processing in generalized anxiety disorder and major depressive disorder: An event-related potential study. *Cognit Ther Res* 2016; **40**: 275-289 [PMID: 27346901 DOI: 10.1007/s10608-015-9717-1]

72 **Lyubomirsky S**, Layous K, Chancellor J, Nelson SK. Thinking about rumination: the scholarly contributions and intellectual legacy of Susan Nolen-Hoeksema. *Annu Rev Clin Psychol* 2015; **11**: 1-22 [PMID: 25581241 DOI: 10.1146/annurev-clinpsy-032814-112733]

73 **Watkins ER**, Mullan E, Wingrove J, Rimes K, Steiner H, Bathurst N, Eastman R, Scott J. Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomised controlled trial. *Br J Psychiatry* 2011; **199**: 317-322 [PMID: 21778171 DOI: 10.1192/bjp.bp.110.090282]

74 **Fan Q**, Li Y, Gao Y, Nazari N, Griffiths MD. Self-Compassion Moderates the Association Between Body Dissatisfaction and Suicidal Ideation in Adolescents: A Cross-Sectional Study. *Int J Ment Health Addict* 2022; 1-18 [PMID: 35039750 DOI: 10.1007/s11469-021-00727-4]

75 **Hoffmann TC**, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ* 2014; **348**: g1687 [PMID: 24609605 DOI: 10.1136/bmj.g1687]

76 **Chueh KH**, Chen KR, Lin YH. Psychological Distress and Sleep Disturbance Among Female Nurses: Anxiety or Depression? *J Transcult Nurs* 2021; **32**: 14-20 [PMID: 31625463 DOI: 10.1177/1043659619881491]

77 **Norton PJ**, Paulus DJ. Transdiagnostic models of anxiety disorder: Theoretical and empirical underpinnings. *Clin Psychol Rev* 2017; **56**: 122-137 [PMID: 28450042 DOI: 10.1016/j.cpr.2017.03.004]

78 **Farchione TJ**, Fairholme CP, Ellard KK, Boisseau CL, Thompson-Hollands J, Carl JR, Gallagher MW, Barlow DH. Unified protocol for transdiagnostic treatment of emotional disorders: a randomized controlled trial. *Behav Ther* 2012; **43**: 666-678 [PMID: 22697453 DOI: 10.1016/j.beth.2012.01.001]

79 **Nazari N**, Sadeghi M, Ghadampour E, Mirzaeefar D. Transdiagnostic treatment of emotional disorders in people with multiple sclerosis: randomized controlled trial. *BMC Psychol* 2020; **8**: 114 [PMID: 33129356 DOI: 10.1186/s40359-020-00480-8]

80 **Rosellini AJ**, Brown TA. The Multidimensional Emotional Disorder Inventory (MEDI): Assessing transdiagnostic dimensions to validate a profile approach to emotional disorder classification. *Psychol Assess* 2019; **31**: 59-72 [PMID: 30160498 DOI: 10.1037/pas0000649]

81 **Macía P**, Gorbeña S, Gómez A, Barranco M, Iraurgi I. Role of neuroticism and extraversion in the emotional health of people with cancer. *Heliyon* 2020; **6**: e04281 [PMID: 32671245 DOI: 10.1016/j.heliyon.2020.e04281]

82 **Fredrickson BL**, Joiner T. Reflections on Positive Emotions and Upward Spirals. *Perspect Psychol Sci* 2018; **13**: 194-199 [PMID: 29592643 DOI: 10.1177/1745691617692106]

83 **Parmentier FBR**, García-Toro M, García-Campayo J, Yañez AM, Andrés P, Gili M. Mindfulness and Symptoms of Depression and Anxiety in the General Population: The Mediating Roles of Worry, Rumination, Reappraisal and Suppression. *Front Psychol* 2019; **10**: 506 [PMID: 30906276 DOI: 10.3389/fpsyg.2019.00506]

84 **Ashworth DK**, Sletten TL, Junge M, Simpson K, Clarke D, Cunnington D, Rajaratnam SM. A randomized controlled trial of cognitive behavioral therapy for insomnia: an effective treatment for comorbid insomnia and depression. *J Couns Psychol* 2015; **62**: 115-123 [PMID: 25867693 DOI: 10.1037/cou0000059]

85 **Eisendrath SJ**, Gillung E, Delucchi KL, Segal ZV, Nelson JC, McInnes LA, Mathalon DH, Feldman MD. A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression. *Psychother Psychosom* 2016; **85**: 99-110 [PMID: 26808973 DOI: 10.1159/000442260]

86 **Ferguson E**. A taxometric analysis of health anxiety. *Psychol Med* 2009; **39**: 277-285 [PMID: 18485260 DOI: 10.1017/S0033291708003322]

87 **Bonanno GA**, Maccallum F, Malgaroli M, Hou WK. The Context Sensitivity Index (CSI): Measuring the Ability to Identify the Presence and Absence of Stressor Context Cues. *Assessment* 2020; **27**: 261-273 [PMID: 30577707 DOI: 10.1177/1073191118820131]

88 **Harvey MM**, Coifman KG, Ross G, Kleinert D, Giardina P. Contextually appropriate emotional word use predicts adaptive health behavior: Emotion context sensitivity and treatment adherence. *J Health Psychol* 2016; **21**: 579-589 [PMID: 24801328 DOI: 10.1177/1359105314532152]

89 **Guendelman S**, Medeiros S, Rampes H. Mindfulness and Emotion Regulation: Insights from Neurobiological, Psychological, and Clinical Studies. *Front Psychol* 2017; **8**: 220 [PMID: 28321194 DOI: 10.3389/fpsyg.2017.00220]

90 **Oser M**, Khan A, Kolodziej M, Gruner G, Barsky AJ, Epstein L. Mindfulness and Interoceptive Exposure Therapy for Anxiety Sensitivity in Atrial Fibrillation: A Pilot Study. *Behav Modif* 2021; **45**: 462-479 [PMID: 31550903 DOI: 10.1177/0145445519877619]

91 **Vogel DL**, Wade NG, Hackler AH. Emotional expression and the decision to seek therapy: The mediating roles of the anticipated benefits and risks. *J Soc Clin Psychol* 2008; **27**: 254-278 [DOI: 10.1521/jscp.2008.27.3.254]

92 **Johnston L**, Titov N, Andrews G, Dear BF, Spence J. Comorbidity and internet-delivered transdiagnostic cognitive behavioural therapy for anxiety disorders. *Cogn Behav Ther* 2013; **42**: 180-192 [PMID: 23458319 DOI: 10.1080/16506073.2012.753108]

93 **Titov N**, Fogliati VJ, Staples LG, Gandy M, Johnston L, Wootton B, Nielssen O, Dear BF. Treating anxiety and depression in older adults: randomised controlled trial comparing guided *v*. self-guided internet-delivered cognitive-behavioural therapy. *BJPsych Open* 2016; **2**: 50-58 [PMID: 27703754 DOI: 10.1192/bjpo.bp.115.002139]

94 **Dear BF**, Fogliati VJ, Fogliati R, Gandy M, McDonald S, Talley N, Holtmann G, Titov N, Jones M. Transdiagnostic internet-delivered cognitive-behaviour therapy (CBT) for adults with functional gastrointestinal disorders (FGID): A feasibility open trial. *J Psychosom Res* 2018; **108**: 61-69 [PMID: 29602327 DOI: 10.1016/j.jpsychores.2018.02.015]

95 **Norouzi M**, Hashemi M, Pouri Z. The Question of Global Society in Post-Corona Time: Towards a Paradigm Shift. *Int J Community Wellbeing* 2021; **4**: 339-343 [PMID: 34723124 DOI: 10.1007/s42413-021-00141-7]

**Footnotes**

**Institutional review board statement:** The study was carried out in accordance with the Declaration of Helsinki and was approved and registered by the ethical and Human Subjects Review. The study was reviewed and approved by the (Bamyan University) Institutional Review Board [(Approval No: BAMAFGHEDU2019070)].

**Clinical trial registration statement:** This study is registered at https://clinicaltrials.gov/ct2/show/NCT04498949. The registration identification number is NCT04498949.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** The datasets generated and/or analyzed during the current study are not publicly available due to (local policy considerations and limitations of ethical approval involving the patient data and anonymity) but are available from the corresponding author upon reasonable request.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Psychological Association, No. C2000157758.

**Peer-review started:** March 11, 2022

**First decision:** April 18, 2022

**Article in press:** July 25, 2022

**Specialty type:** Behavioral sciences

**Country/Territory of origin:** Iran

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Caiado B, Portugal; Gálvez-Lara M,Spain **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 participants flow chart diagram.** ITT: intent to treat.

**Table 1 Study schedule of enrollment, intervention, and assessment**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Enrollment** | **Pre-allocation** | **Allocation** | **Post-intervention** |
| Duration | 12 wk | 1 wk | 12 wk | |
| Eligibility | x |  |  |  |
| Informed consent | x |  |  |  |
| Clinical interview | x |  |  | x |
| Demographic question | x |  |  |  |
| Intervention | | | | |
| Unified protocol |  |  | - | |
| Treatment as usual |  |  | - | |
| Primary outcome | | | | |
| OASIS |  | x |  | x |
| ODSIS |  | x |  | x |
| Secondary outcomes | | | | |
| DERS |  | x |  | x |
| ESQ |  | x |  | x |
| PANAS |  | x |  | x |

x: completed at this stage; -: Intervention period. DERS: Difficulties in Emotion Regulation Scale; ESQ: Emotional Style Questionnaire; OASIS: Overall Anxiety Severity and Impairment Scale; ODSIS: The Overall Depression Severity and Impairment Scale; PANAS: Positive and Negative Affect Schedule.

**Table 2 Content and the number of sessions for each module**

|  |  |  |
| --- | --- | --- |
| **Module** | **Schedule** | **Content and the number of sessions for each module** |
| One1 | Week 1 | Setting goals and maintaining motivation (1 session) |
| Two1 | Week 2 | Understanding emotions (1 sessions) |
| Three2 | Week 3 and 41 | Mindful emotion awareness (2 sessions) |
| Four2 | Week 5 | Cognitive flexibility (2 sessions) |
| Five2 | Week 6 | Countering emotional behaviors (1 sessions) |
| Six2 | Week 7 | Understanding and confronting physical sensations (1 session) |
| Seven2 | Weeks 8 to 11 | Emotion exposures (5 sessions) |
| Eight3 | Week 12 | Recognizing accomplishments and looking to the future (1 session) |

1the modules of three, four, five, six, and seven are core modules.

2the modules of one and two are introductory modules.

3the module of eight is the relapse introductory module.

**Table 3 Demographic characteristics of the sample, *n* = 102**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Item characteristic** | **Baseline value** | **Control group value** | **UP group value** | **Test** | ***p* value** |
| **Categorical variables** | | | | | |
| Sex*, n* (%) |  |  |  |  |  |
| Women | 48 (47.1) | 21 | 27 | *χ*² = 0.35 | 0.55 |
| Man | 54 (52.9) | 30 | 24 |  |  |
| Principal diagnosis, *n* (%) |  |  |  |  |  |
| Depressive disorder | 45 (44.1) | 22 | 23 | *χ*² = 1.41 | 0.23 |
| Anxiety disorder | 57 (55.9) | 26 | 31 |  |  |
| Marital status*, n* (%) |  |  |  |  |  |
| Single | 34 (33.3) | 20 | 14 | *χ*² = 11.33 | 0.001 |
| In relationship | 68 (66.7) | 35 | 33 |  |  |
| Psychological disorders, *n* (%) |  |  |  |  |  |
| MDD | 40 (48.6) | 18 | 22 |  |  |
| Dysthymia | 5 (7.1) | 4 | 1 |  |  |
| GAD | 34 (31.4) | 15 | 19 |  |  |
| SAD | 23 (12.9) | 11 | 12 |  |  |
| **Continues variables (mean ± SD)** | | | | | |
| Age, yr | 28.07 ± 5.07 | 27.92 ± 4.67 | 28.18 ± 5.49 | *t*(100)=0.28 | 0.77 |
| Anxiety | 11.14 ± 1.88 | 11.35 ± 2.05 | 10.88 ± 1.69 | *t*(100*)* =1.26 | 0.21 |
| Depression | 10.97 ± 3.75 | 11.24 ± 1.75 | 10.71 ± 1.70 | *t*(100*)* =1.09 | 0.26 |
| Emotion dysregulation | 49.69 ± 7.82 | 49.08 ± 7.10 | 50.18 ± 8.04 | *t*(100*)* =0.80 | 0.4 |
| Positive affect | 26.49 ± 3.80 | 26.88 ± 3.92 | 26.10 ± 3.66 | *t*(100)=1.05 | 0.29 |
| Negative affect | 27.44 ± 3.42 | 26.59 ± 3.66 | 27.74 ± 3.01 | *t*(100)=1.48 | 0.14 |
| Healthy emotionality | 59.84 ± 8.82 | 60.33 ± 9.46 | 58.90 ± 11.35 | *t*(100) *=* 1.67 | 0.09 |

GAD: generalized anxiety disorder; MDD: major depressive disorder; SAD: social anxiety disorder; SD: Standard deviation; *t*: independent *t*-test; UP: Unified protocol.

**Table 4 Analysis of covariance at Time 2 to compare the unified protocol with treatment as usual**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Measure** | **Condition** | **Adjusted mean** | | **Levene’s test** | | **ANCOVA** | | | |
| **TAU** | **UP** | ***F* (1, 100)** | **Sig** | ***F* (1, 99)** | ***P* value** | **η2*p*** | ***R*2** |
| Anxiety | | | | | | | | | |
|  | Time 2 | 11.81 | 7.98 | 3.67 | 0.058 | 28.77 | < 0.001 | 0.22 | 0.23 |
| Depression | | | | | | | | | |
|  | Time 2 | 12.11 | 8.03 | 3.43 | 0.07 | 62.02 | < 0.001 | 0.38 | 0.37 |
| Emotion dysregulation | | | | | | | | | |
|  | Time 2 | 52.44 | 48.06 | 2.34 | 0.12 | 6.57 | 0.012 | .06 | 0.07 |
| Positive affect | | | | | | | | | |
|  | Time 2 | 26.72 | 33.14 | 0.12 | 0.68 | 40.75 | < 0.001 | 0.29 | 0.30 |
| Negative affect | | | | | | | | | |
|  | Time 2 | 27.01 | 23.28 | 1.87 | 0.17 | 21.35 | < 0.001 | 0.18 | 0.16 |
| Healthy emotionality | | | | | | | | | |
|  | Time 2 | 58.83 | 65.68 | 0.19 | 0.68 | 12.90 | 0.001 | 0.12 | 0.14 |

ANCOVA: analysis of covariance; η2p: partial eta square; R2: adjusted R square; TAU: Treatment as usual; Time 2: immediately after treatment; UP: Unified Protocol.

**Table 5 control group and intervention group**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Measure** | **Control group (TaU), *n =* 51** | | **Intervention group (UP), *n =* 51** | |
| **Time 1** | **Time 1I** | **Time 1** | **Time 1i** |
| Anxiety | 11.35 ±2.05 | 11.75 ± 2.42 | 10.88 ± 1.69 | 8.54 ± 2.83 |
| Depression | 11.24 ± 1.75 | 12.08 ± 2.16 | 10.71 ± 1.70 | 8.14 ± 3.03 |
| Emotion difficulties | 49.07 ± 7.32 | 50.31 ± 8.40 | 50.18 ± 8.04 | 47.33 ± 9.41 |
| Positive affect | 26.88 ± 3.92 | 26.99 ± 4.22 | 26.10 ± 3.66 | 31.97 ± 3.59 |
| Negative affect | 26.59 ± 3.66 | 27.89 ± 3.74 | 27.74 ± 3.01 | 23.31 ± 4.92 |
| Healthy emotionality | 60.33 ± 9.46 | 59.47 ± 10.41 | 58.90 ± 11.35 | 65.12 ± 10.76 |

Data are presented as mean ± SD.Time 1I: posttreatment; TAU: treatment as usual; UP: unified protocol.

**Table 6 Paired *t*-test and within-group effect size at post-intervention**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Item** | **Treatment as usual group** | | **Unified protocol group** | | |
| ***t*(50)** | ***P* value** | ***t*(50)** | ***P* value** | ***Cohen’s d*** |
| Anxiety | 0.88 | 0.37 | 6.13 | < 0.001 | 0.81 |
| Depression | -1.89 | 0.06 | 4.38 | < 0.001 | 0.75 |
| Emotion difficulties | -0.98 | 0.33 | 5.45 | < 0.001 | 0.54 |
| Positive affect | 0.12 | 0.8 | -7.92 | < 0.001 | 1.39 |
| Negative affect | -0.36 | 0.72 | 4.43 | < 0.001 | 0.83 |
| Healthy emotionality | 0.53 | 0.6 | -2.16 | 0.03 | 0.39 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**